The global c-reactive protein analyzers market size is expected to reach US$ 7.8 Billion in 2032 and exhibit growth at a CAGR of 3.8% in the forecast period from 2022 to 2032. It is likely to reachUS$ 4.6 Billion in 2022. The increasing prevalence of cancers, diabetes, and inflammatory disorders is projected to drive the demand for c-reactive protein analyzers in the upcoming years.
| C-Reactive Protein Analyzers Market Estimated Base Year Value (2021) | US$ 3.1 Billion |
| C-Reactive Protein Analyzers Market Expected Market Value (2022) | US$ 4.6 Billion |
| C-Reactive Protein Analyzers Market Anticipated Forecast Value (2032) | US$ 7.8 Billion |
| C-Reactive Protein Analyzers Market Projected Growth Rate (2022-2032) | 3.8% CAGR |
C-reactive protein is considered to be a significant marker for the diagnosis of inflammation in an individual’s body. It is mainly produced in the liver and is detected in one’s blood if there is any inflammation in the body.
Heart attack and rheumatoid arthritis can often raise the level of c-reactive protein in the blood. The latest analyzers are capable of detecting numerous infections in the body, such as skin infections and pneumonia.
These analyzers can also identify traumas, burns, tuberculosis, and inflammatory bowel disease that surge the level of c-reactive protein. Many healthcare professionals are set to use these analyzers to observe the effectiveness of a particular treatment for a specific inflammatory disease.
The ongoing technological advancement in the healthcare sector and the rising adoption of point of care devices are two of the major factors that are likely to propel the sales of c-reactive protein analyzers in future years. The emergence of cutting-edge nanotechnological tools that can provide a lucrative perspective in developing portable bioanalytical assays with high sensitivity and multiplexing capabilities is another vital factor that is anticipated to bode well for the market.
The increasing usage of immunoturbidimetric assays in case of chronic disorders of the respiratory and cardiac systems is also estimated to contribute to this growth. The ongoing development of the Chemiluminescence Immunoassay (CLIA) technique to deliver accurate results is anticipated to augment the growth.
The adoption of c-reactive protein analyzers may get hampered in the assessment period because of certain risks associated with these tests, such as infection at the puncture site, dizziness, and excessive bleeding. Besides, the lack of awareness among people about these tests in emerging countries, such as India and China may obstruct the sales of c-reactive protein analyzers.
North America is anticipated to remain at the forefront by generating the largest c-reactive protein analyzers market share in the forthcoming years. The presence of several renowned companies and a well-established healthcare infrastructure in Canada and the U.S. are anticipated to bolster the regional market.
The increasing prevalence of cardiovascular diseases and the rising number of new product launches are two of the other crucial factors that are set to push the market. As per the Centers for Disease Control and Prevention (CDC), in the U.S., nearly 659,000 people die from heart disease every year and about 805,000 people suffer from heart attack each year in the country. These numbers are likely to surge at a rapid pace in the evaluation period, thereby boosting the North America market.
The rising incidence of cancer in India and China is likely to accelerate the Asia Pacific c-reactive protein analyzers market growth in the assessment period. According to the American Society of Clinical Oncology Journal, in 2020, approximately 679,421 males and 712,758 females were living with cancer in India. This trend is set to continue in the near future, thereby driving the Asia Pacific market.
The COVID-19 pandemic that broke out in December 2019 also pushed sales of these analyzes in this region. Many healthcare institutions were conducting numerous studies to examine c-reactive protein as a prognostic indicator in patients suffering from coronavirus. Spurred by the aforementioned factors, the market in Asia Pacific is estimated to grow at a rapid pace.
Some of the reputed companies operating in the global c-reactive protein analyzers market include Orion Diagnostica, Dr. Müller Gerätebau GmbH, SD Biosensor, Eurolyser Diagnostica GmbH, Nano-Ditech Corp., Abbott, Sugentech, Inc., Paramedical s.r.l., and biosurfit SA among others.
The global market is highly competitive and fragmented in nature. Majority of the key players are focusing on partnerships and collaborations to expand their management facilities, distribution networks, and product portfolios. Meanwhile, a few other key players are striving to invest huge sums in research and development activities to introduce novel products.
| Report Attribute | Details |
| Growth Rate | CAGR of 3.8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Indication:
By End Users:
By Region:
The global c-reactive protein analyzers market is anticipated to exceed US$ 7.8 Billion in 2032.
North America is likely to dominate the c-reactive protein analyzers market in the forecast period.
Orion Diagnostica, Dr. Müller Gerätebau GmbH, SD Biosensor, Eurolyser Diagnostica GmbH, Nano-Ditech Corp., and Abbott are some of the renowned companies in the c-reactive protein analyzers market.
Explore Similar Insights
C-Reactive Protein Analyzers Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
